AU3895000A - Treatment of posttraumatic stress disorder, obsessive-compulsive disorder and related neuropsychiatric disorders - Google Patents

Treatment of posttraumatic stress disorder, obsessive-compulsive disorder and related neuropsychiatric disorders

Info

Publication number
AU3895000A
AU3895000A AU38950/00A AU3895000A AU3895000A AU 3895000 A AU3895000 A AU 3895000A AU 38950/00 A AU38950/00 A AU 38950/00A AU 3895000 A AU3895000 A AU 3895000A AU 3895000 A AU3895000 A AU 3895000A
Authority
AU
Australia
Prior art keywords
disorder
obsessive
treatment
neuropsychiatric disorders
posttraumatic stress
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU38950/00A
Other languages
English (en)
Inventor
Barry S. Fogel
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Synchroneuron Inc
Original Assignee
Synchroneuron Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Synchroneuron Inc filed Critical Synchroneuron Inc
Publication of AU3895000A publication Critical patent/AU3895000A/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
AU38950/00A 1999-03-19 2000-03-17 Treatment of posttraumatic stress disorder, obsessive-compulsive disorder and related neuropsychiatric disorders Abandoned AU3895000A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US09273036 1999-03-19
US09/273,036 US6391922B1 (en) 1998-01-13 1999-03-19 Treatment of posttraumatic stress disorder, obsessive-compulsive disorder and related neuropsychiatric disorders
PCT/US2000/007119 WO2000056301A2 (en) 1999-03-19 2000-03-17 Treatment of posttraumatic stress disorder, obsessive-compulsive disorder and related neuropsychiatric disorders

Publications (1)

Publication Number Publication Date
AU3895000A true AU3895000A (en) 2000-10-09

Family

ID=23042279

Family Applications (1)

Application Number Title Priority Date Filing Date
AU38950/00A Abandoned AU3895000A (en) 1999-03-19 2000-03-17 Treatment of posttraumatic stress disorder, obsessive-compulsive disorder and related neuropsychiatric disorders

Country Status (6)

Country Link
US (2) US6391922B1 (https=)
EP (1) EP1162960A2 (https=)
JP (1) JP4633262B2 (https=)
AU (1) AU3895000A (https=)
CA (1) CA2367015A1 (https=)
WO (1) WO2000056301A2 (https=)

Families Citing this family (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6391922B1 (en) * 1998-01-13 2002-05-21 Synchroneuron, Llc Treatment of posttraumatic stress disorder, obsessive-compulsive disorder and related neuropsychiatric disorders
US20020022657A1 (en) * 1998-02-11 2002-02-21 Francine Gervais Methods for modulating neuronal cell death
EP1852113A3 (en) * 2000-12-07 2008-03-12 Neuromolecular Inc. Methods for treating neuropsychiatric disorders with NMDA receptors antagonists
AU2002311784B2 (en) * 2001-03-29 2007-11-22 Michael Davis Acute pharmacologic augmentation of psychotherapy with enhancers of learning or conditioning
US6462084B1 (en) * 2001-05-14 2002-10-08 Brookhaven Science Associates, Llc Treatment for obsessive-compulsive disorder (OCD) and OCD-related disorders using GVG
US20030045541A1 (en) * 2001-07-23 2003-03-06 Christopher Bruckner GABA-Receptor modulators with NMDA-Antagonistic activity
US20040034106A1 (en) * 2001-11-06 2004-02-19 Read Holly Ann Treatment of anxiety disorders
EP1471909A4 (en) * 2002-01-16 2007-07-25 Endo Pharmaceuticals Inc PHARMACEUTICAL COMPOSITION AND METHOD FOR THE TREATMENT OF DISEASES OF THE CENTRAL NERVOUS SYSTEM
JPWO2004093910A1 (ja) * 2003-04-22 2006-07-13 アステラス製薬株式会社 ＰＰＡＲδアゴニストによる脳神経変性疾患治療剤
US7396535B2 (en) * 2003-04-25 2008-07-08 Ackerman Alan H Therapy for obsessive compulsive head banging
US7390496B2 (en) * 2003-04-25 2008-06-24 Allergan, Inc. Therapeutic treatments for repetitive hand washing
US7422753B2 (en) * 2003-04-25 2008-09-09 Allergan, Inc. Methods for treating trichotillomania
US7393537B2 (en) * 2003-04-25 2008-07-01 Allergan, Inc. Botulinum toxin for treatment of obsessive compulsive finger biting disorder
WO2005056574A2 (en) * 2003-12-09 2005-06-23 Yeda Research And Development Co. Ltd. Method and vaccine comprising copolymer 1 for treatment of psychiatric disorders
US8609112B2 (en) 2003-10-29 2013-12-17 Allergan, Inc. Botulinum toxin treatments of depression
US8617572B2 (en) 2003-10-29 2013-12-31 Allergan, Inc. Botulinum toxin treatments of depression
US8734810B2 (en) 2003-10-29 2014-05-27 Allergan, Inc. Botulinum toxin treatments of neurological and neuropsychiatric disorders
US8609113B2 (en) 2003-10-29 2013-12-17 Allergan, Inc. Botulinum toxin treatments of depression
US7619007B2 (en) 2004-11-23 2009-11-17 Adamas Pharmaceuticals, Inc. Method and composition for administering an NMDA receptor antagonist to a subject
EP1831173B1 (en) * 2004-12-17 2011-01-26 Janssen Pharmaceutica NV Tetrahydroisoquinoline compounds for treatment of cns disorders
US20060167068A1 (en) * 2005-01-26 2006-07-27 Seth Feuerstein Method of treating self-injurious behavior with glutamate modulating agents
US8778979B2 (en) * 2005-04-05 2014-07-15 Yale University Glutamate agents in the treatment of mental disorders
JP5666087B2 (ja) 2005-04-06 2015-02-12 アダマス・ファーマシューティカルズ・インコーポレーテッド Ｃｎｓ関連疾患の治療のための方法及び組成物
US20060252830A1 (en) * 2005-05-06 2006-11-09 Brandon Stephen F Method for the treatment of magnesium and potassium deficiencies
US20060252831A1 (en) * 2005-05-06 2006-11-09 Christopher Offen Method for the treatment of magnesium and potassium deficiencies
EP1928445A1 (en) * 2005-09-16 2008-06-11 Cereuscience AB Method and means of preventing and treating sleep disordered breathing
EP1968561B8 (en) * 2005-12-22 2010-10-20 Kiacta Sàrl Treatment of diabetic nephropathy
WO2008078176A1 (en) * 2006-12-22 2008-07-03 Bellus Health (International) Limited Methods, compounds, and compositions for treating metabolic disorders and diabetes
US20080171750A1 (en) * 2007-01-11 2008-07-17 Braincells, Inc. Modulation Of Neurogenesis With Use of Modafinil
US20090104160A1 (en) * 2007-02-01 2009-04-23 Moraga Biotechnology Corporation Mobilization of Stem Cells After Trauma and Methods Therefor
JP2010534676A (ja) * 2007-07-23 2010-11-11 シノシア・セラピューティクス 心的外傷後ストレス障害の治療
US20090082464A1 (en) * 2007-09-07 2009-03-26 Bernd Jandeleit Externally masked neopentyl sulfonyl ester cyclization release prodrugs of acamprosate, compositions thereof, and methods of use
EP2217564A1 (en) * 2007-09-07 2010-08-18 XenoPort, Inc. Complex pantoic acid ester neopentyl sulfonyl ester cyclization release prodrugs of acamprosate, compositions thereof, and methods of use
US20090099253A1 (en) * 2007-10-15 2009-04-16 Xenoport, Inc. Internally Masked Neopentyl Sulfonyl Ester Cyclization Release Prodrugs of Acamprosate, Compositions Thereof, and Methods of Use
US20090156886A1 (en) * 2007-12-12 2009-06-18 Synapse Research Company Method and apparatus for providing automatic eye focused therapy
EP2135607A1 (en) 2008-06-18 2009-12-23 Pharnext Combination of pilocarpin and methimazol for treating Charcot-MarieTooth disease and related disorders
CA2781830C (en) 2009-02-12 2018-03-27 Indiana University Research & Technology Corporation Materials and methods for treating developmental disorders including comorbid and idiopathic autism
US9125907B2 (en) 2009-09-30 2015-09-08 Christopher Shaari Use of botulinum neurotoxin to treat substance addictions
US9387206B2 (en) 2009-11-03 2016-07-12 Pharnext Therapeutic approaches for treating Alzheimer's disease
EP2322163A1 (en) 2009-11-03 2011-05-18 Pharnext New therapeutics approaches for treating alzheimer disease
MX346203B (es) 2010-09-28 2017-03-09 Depomed Inc Formas de dosificacion retentivas gastricas para liberacion prolongada de acamprosato en el tracto gastrointestinal superior.
EP3034079B1 (en) 2010-11-15 2018-01-10 Agenebio, Inc. Pyridazine derivatives, compositions and methods for treating cognitive impairment
US9248111B2 (en) 2011-03-01 2016-02-02 Pharnext Therapeutic approaches for treating parkinson's disease
TR201809351T4 (tr) * 2011-03-01 2018-07-23 Pharnext Nörolojik bozuklukların baklofen ve akamprosat tabanlı terapisi.
EP2705842A1 (en) * 2012-09-05 2014-03-12 Pharnext Therapeutic approaches for treating parkinson's disease
US10010515B2 (en) 2011-03-01 2018-07-03 Pharnext Therapeutic approaches for treating Parkinson's disease
US9241933B2 (en) 2011-03-01 2016-01-26 Pharnext Compositions for treating amyotrophic lateral sclerosis
CN104487064B (zh) * 2012-03-01 2018-01-26 法耐斯特公司 用于治疗肌萎缩性侧索硬化症的新组合物
US20130143867A1 (en) * 2011-12-02 2013-06-06 Sychroneuron Inc. Acamprosate formulations, methods of using the same, and combinations comprising the same
JP6722453B2 (ja) * 2012-08-23 2020-07-15 スチュアート エル ウェグ 抗不安薬組成物、製剤および使用方法
WO2014197744A1 (en) 2013-06-05 2014-12-11 Synchroneuron, Inc. Acamprosate formulations, methods of using the same, and combinations comprising the same
EP3083569B1 (en) 2013-12-20 2022-01-26 Agenebio, Inc. Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
US9717903B1 (en) * 2015-03-17 2017-08-01 Gary Barrett Electronic process to restore, improve and/or strengthen the libido; method to mend the sex drive in males and females
US10431109B2 (en) * 2015-06-03 2019-10-01 Cambia Health Solutions, Inc. Systems and methods for somatization identification and treatment
JP6987384B2 (ja) 2015-06-19 2021-12-22 エージンバイオ， インコーポレイテッド ベンゾジアゼピン誘導体、組成物、および認知障害を処置するための方法
US20180170941A1 (en) 2016-12-19 2018-06-21 Agenebio, Inc. Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
US11505555B2 (en) 2016-12-19 2022-11-22 Agenebio, Inc. Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
RU2019143572A (ru) 2017-05-25 2021-06-25 Глитек Ллс. Композиции для лечения посттравматического стрессового расстройства
US10682086B2 (en) * 2017-09-12 2020-06-16 AebeZe Labs Delivery of a digital therapeutic method and system
US11157700B2 (en) * 2017-09-12 2021-10-26 AebeZe Labs Mood map for assessing a dynamic emotional or mental state (dEMS) of a user
US11414425B2 (en) 2018-06-19 2022-08-16 Agenebio, Inc. Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
US11694786B1 (en) * 2019-01-04 2023-07-04 Yasmine Van Wilt Recommendation methods, systems and devices
PH12022551856A1 (en) 2020-01-22 2024-01-03 Seelos Therapeutics Inc Reducing side effects of nmda antagonists
WO2025106574A1 (en) 2023-11-14 2025-05-22 Aardwolf Therapeutics, Inc. Flumazenil for treating post-traumatic stress disorder and anxiety

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2457281A1 (fr) 1979-05-23 1980-12-19 Meram Lab Nouveaux derives de l'acide 3-aminopropanesulfonique ayant une activite membranaire renforcee
US4745126A (en) 1987-03-12 1988-05-17 Eli Lilly And Company Method of treating anxiety with tetrahydrobenz[c,d]indole-6-carboxamides
US4985256A (en) 1988-04-27 1991-01-15 Bionix Corporation Methods for diagnosing, monitoring and controlling the onset and progression of certain dementias and impeding memory loss or improving impairment of memory
US4962128A (en) 1989-11-02 1990-10-09 Pfizer Inc. Method of treating anxiety-related disorders using sertraline
US5028612A (en) 1990-03-22 1991-07-02 Hillel Glover Method for treating emotional numbness
US5086072A (en) 1990-06-18 1992-02-04 The United States Of America As Represented By The Department Of Health And Human Services Treatment of mood disorders with functional antagonists of the glycine/nmda receptor complex
US5145866A (en) 1991-04-22 1992-09-08 Hoechst-Roussel Pharmaceuticals Incorporated Method of treating anxiety with the aid of r(+)-3-amino-1-hydroxy-pyrrolidin-2-one
US5602150A (en) 1992-10-02 1997-02-11 Research Foundation For Mental Hygiene, Inc. Treatment of central nervous system disorders associated with psychotic behavior and dementia with a combination of neuroleptic drugs and taurine, or derivatives thereof, to prevent the development of tardive dyskinesia
US5356902A (en) 1992-11-06 1994-10-18 Eli Lilly And Company Decahydroisoquinoline compounds as excitatory amino acid receptor antagonists
US5475019A (en) 1993-02-08 1995-12-12 East Carolina University Method of treating anxiety-related disorders with 2-aminocycloaliphatic amide compounds
US5475007A (en) 1993-05-28 1995-12-12 The Regents Of The University Of California 1,2,3,4-tetrahydroquinoline-2,3,4-trione-3 or 4-oximes and the use thereof
US5665757A (en) 1994-07-13 1997-09-09 Robert W. Dunn Method for treating anxiety
US5597922A (en) 1994-07-29 1997-01-28 State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University And The University Of Oregon Glycine receptor antagonist pharmacophore
US6562862B1 (en) 1994-10-20 2003-05-13 Eli Lilly And Company Methods of inhibiting physiological conditions associated with an excess of neuropeptide Y
US5574028A (en) 1994-10-31 1996-11-12 Eli Lilly And Company Method for treating anxiety
US5484794A (en) 1994-11-09 1996-01-16 Eli Lilly And Company Method for treating anxiety
US5726193A (en) 1994-10-31 1998-03-10 Eli Lilly And Company Method for treating anxiety
US5488056A (en) 1994-10-31 1996-01-30 Eli Lilly And Company Method for treating anxiety
US5476933A (en) 1994-11-16 1995-12-19 State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University And The University Of Oregon Azepine synthesis via a diels-alder reaction
US5654303A (en) 1995-06-07 1997-08-05 Warner-Lambert Company Alkyl amine derivatives of substituted quinoxaline 2,3-diones as glutamate receptor antagonists
US5614508A (en) 1995-06-07 1997-03-25 Warner-Lambert Company Amino acid derivatives of substituted quinoxaline 2,3-dione derivatives as glutamate receptor antagonists
US5763457A (en) 1995-11-13 1998-06-09 Eli Lilly And Company Method for treating anxiety
US5852037A (en) 1995-11-13 1998-12-22 Eli Lilly And Company Method for treating anxiety
US5681578A (en) 1996-01-22 1997-10-28 Sahley; Billie J. Composition for relieving stress anxiety, grief, and depression
US5776969A (en) 1997-02-27 1998-07-07 Eli Lilly And Company Treatment of sleep disorders
US5866585A (en) 1997-05-22 1999-02-02 Synchroneuron, Llc Methods of treating tardive dyskinesia using NMDA receptor antagonists
US5883083A (en) 1997-06-09 1999-03-16 Harlmen, Inc. Dietary supplement for alleviating behavioral problems in canines and reducing seizures in canines and felines
US6294583B1 (en) 1998-01-13 2001-09-25 Synchroneuron, Llc Methods of treating tardive dyskinesia and other movement disorders
WO1999036064A2 (en) 1998-01-13 1999-07-22 Synchroneuron, Llc Methods of treating tardive dyskinesia and other movement disorders
US6391922B1 (en) * 1998-01-13 2002-05-21 Synchroneuron, Llc Treatment of posttraumatic stress disorder, obsessive-compulsive disorder and related neuropsychiatric disorders

Also Published As

Publication number Publication date
JP2002539245A (ja) 2002-11-19
US6689816B2 (en) 2004-02-10
US20020119912A1 (en) 2002-08-29
CA2367015A1 (en) 2000-09-28
EP1162960A2 (en) 2001-12-19
US6391922B1 (en) 2002-05-21
JP4633262B2 (ja) 2011-02-16
WO2000056301A3 (en) 2000-12-28
WO2000056301A2 (en) 2000-09-28

Similar Documents

Publication Publication Date Title
AU3895000A (en) Treatment of posttraumatic stress disorder, obsessive-compulsive disorder and related neuropsychiatric disorders
AU9262598A (en) Interferon-gamma-binding molecules for treating septic shock, cachexia, immune diseases and skin disorders
MXPA03007960A (es) Compuestos y metodos para el tratamiento de desordenes urogenitales.
ZA200003392B (en) Cutting elements and methods of manufacture thereof.
AU4134001A (en) Methods for treating conditions and illnesses associated with abnormal vasculature
AU2001253411A1 (en) Medical dressing assembly and associated method of using the same
AU4520697A (en) Use of substituted benzazoles as UV absorbers, new benzazoles and processes for their preparation
ZA200108446B (en) Novel method of treatment.
AU6910600A (en) Methods for the treatment of mental disorders
MXPA02003174A (es) Combinacion novedosa de loteprednol y antihistaminicos.
AU5547000A (en) Novel treatment
AU2001268422A1 (en) Agmatine and agmatine analogs in the treatment of epilepsy, seizure, and electroconvulsive disorders
AU2035401A (en) Lubricant combination and process for the preparation thereof
ZA979731B (en) Treatment of asthma.
ZA986363B (en) Novel method of treatment.
ZA200003768B (en) Methods and compositions for treating diseases and conditions of the eye.
AU2001256855A1 (en) Preparation for the prevention and treatment of ocular disorders
ZA985237B (en) Novel method of treatment.
AU5298699A (en) Dnazymes and methods for treating hpv-related disorders
ZA978640B (en) Use of 1-hydroxy-2-pyridones for the treatment of saborrheic dermatitis.
AU7750100A (en) Method for the treatment of obesity
AU7106300A (en) Treatment of skin disorders
AU7595298A (en) Azolidinediones useful for the treatment of diabetes, dyslipidemia and hy pertension
AU4556800A (en) Novel treatment
ZA973843B (en) Treatment of asthma with TNFR-lg.

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase